Hansoh Pharmaceutical Group Company Limited
3692
Rank in Stocks
#906
Hansoh Pharmaceutical Group Company Limited, an investment holding company,... Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Mailingda, Hengsen, Oulanning, Ailanning, and Ameining; XINYUE; and Saint Luolai, Fulaimei, Ruibote, Fulaidi, Fulairui, Punuoan tablets, etc. It has licence agreements with GlaxoSmithKline Intellectual Property (No.4) Limited to develop, manufacture, and commercialize HS-20089 and HS-20093 for the treatment of patients with extensive-stage small-cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy; Biotheus Inc. to develop, produce, and commercialize bispecific antibody-drug conjugate product; and with Merck Sharp & Dohme LLC (MSD) to develop, manufacture, and commercialize HS-10535, an investigational pre-clinical oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist. The company was founded in 1995 and is headquartered in Shanghai, China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd.
Share Price
$4.40
Market Cap
$26.66B
Change (1 day)
8.32%
Change (1 year)
-6.19%
Country
CN
Trade Hansoh Pharmaceutical Group Company Limited (3692)
Category
Healthcare
P/E ratio for Hansoh Pharmaceutical Group Company Limited (3692)
P/E ratio as of October 2026 TTM: 24.38
According to Hansoh Pharmaceutical Group Company Limited latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 24.38. At the end of 2023 the company had a P/E ratio of 27.33.
P/E ratio history for Hansoh Pharmaceutical Group Company Limited from 2016 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | 24.38 | 10.75% |
| 2024 | 22.01 | -19.44% |
| 2023 | 27.33 | -8.92% |
| 2022 | 30.00 | -11.16% |
| 2021 | 33.77 | -53.33% |
| 2020 | 72.36 | 45.98% |
| 2019 | 49.57 | -3.40% |
| 2018 | 51.31 | -11.60% |
| 2017 | 58.04 | -13.97% |
| 2016 | 67.47 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 34.96 | 43.42% |
IN
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.